Updated:
Rezolute
Rezolute, led by Nevan Elam, targets congenital hyperinsulinism with RZ358, a monoclonal antibody in Phase 3 trials.
Rezolute
Rezolute was founded in 2010 and rebranded from AntriaBio after a 2017 merger reshaped its pipeline. Nevan Charles Elam, a former Wilson Sonsini attorney and ex-head of Nektar Therapeutics' pulmonary business, has led the company as CEO since its early private days. The firm operates as a clinical-stage biopharmaceutical company rather than a traditional asset manager, pursuing drug development over financial returns in the classical sense. The company's lead asset, RZ358 (ersodetug), is a monoclonal antibody that works as an allosteric inhibitor of the insulin receptor. Unlike earlier insulin-targeting drugs that caused dangerous side effects, RZ358 modulates insulin signaling only when blood sugar drops dangerously low. Rezolute runs parallel Phase 3 trials for congenital hyperinsulinism under the names sunRIZE and sugarGO. The congenital hyperinsulinism population is small — roughly 1 in 25,000 to 50,000 live births — placing the company squarely in the orphan-disease space with potential for priority regulatory review. Rezolute also holds RZ402, an oral treatment for diabetic macular edema, expanding its reach into ophthalmology. The firm went public via a reverse-merger in 2014 and trades on Nasdaq under the ticker RZLT. As a public company, it discloses financial and operational details through SEC filings rather than private capital reports. In March 2024, Rezolute secured $100 million in a registered direct offering from a syndicate of institutional healthcare investors, extending its cash runway to fund the ongoing Phase 3 programs. This financing, structured as a private investment in public equity, brought in new life-sciences specialist funds while diluting existing shareholders. Rezolute's structure as a publicly traded biotech targeting ultra-rare metabolic disorders differentiates it from the private venture-backed models that dominate orphan-drug development. The company's pipeline relies on a single platform idea — modulating aberrant insulin signaling at the receptor level — applied across two distinct indications with limited therapeutic overlap. This concentration risk is balanced by the orphan-designation economics, which allow for accelerated development pathways and extended market exclusivity if approved.
General information
Firm type
Asset Manager
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Redwood City
Corporate office
Redwood City, CA, United States
Principals
Nevan Charles Elam
Chief Executive Officer
Sector focus
Frequently asked questions
Is Rezolute a family office or an asset manager?
Rezolute is neither a family office nor a traditional asset manager. It is a publicly traded clinical-stage biopharmaceutical company (Nasdaq: RZLT) focused on developing therapies for rare metabolic diseases. The firm generates no investment returns for external capital; it develops drug candidates and raises equity capital through public offerings. Its inclusion in family-office or asset-manager databases appears to be a misclassification.
What is Rezolute's lead drug candidate and what disease does it target?
Rezolute's lead candidate is RZ358 (ersodetug), a fully human monoclonal antibody designed to treat congenital hyperinsulinism. The drug acts as an allosteric inhibitor of the insulin receptor, stepping in only when blood sugar drops too low and reducing the risk of severe hypoglycemia. It is currently being evaluated in two global Phase 3 clinical trials called sunRIZE and sugarGO.
Who leads Rezolute and what is their background?
Nevan Charles Elam serves as CEO and has led Rezolute since its early private days. Before Rezolute, he was a partner at Wilson Sonsini Goodrich & Rosati and later headed the pulmonary business unit at Nektar Therapeutics. His background blends biopharma operational experience with legal expertise in life-sciences transactions.
How is Rezolute funded?
Rezolute funds its operations through equity raises as a public company. Its most recent major financing was a registered direct offering in March 2024 that brought in roughly $100 million from a syndicate of healthcare-focused institutional investors. The company uses this capital to advance its clinical trials, primarily the Phase 3 programs for RZ358.
What is the structural differentiator in Rezolute's drug mechanism?
RZ358 works as a negative allosteric modulator of the insulin receptor rather than a full antagonist. This means it dampens insulin signaling proportionally to the excess insulin present, rather than blocking the receptor outright. In theory, this reduces efficacy risk when blood sugar is normal and lowers the chance of hyperglycemic side effects — a problem that plagued earlier-generation insulin-targeting compounds in this disease space.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: